News | July 08, 2009

First Patient Enrollment in Clinical Trial for Cellular Treatment of Peripheral Artery Disease

July 8, 2009 - Pluristem Therapeutics Inc. said yesterday its first patient enrolled in a phase I clinical trial that will evaluate the safety of the company’s allogeneic, placental-derived, adherent stromal cell product, termed PLX-PAD. The product is for use in patients afflicted with critical limb ischemia (CLI), the end-stage of peripheral artery disease (PAD). Up to 15 adults with the disease will be included in the trial, which is being conducted at the Franziskus-Krankenhaus Hospital and Charité - Universitätsmedizin Hospital in Berlin.

The Paul Ehrlich Institute recently approved the company to begin clinical trials with PLX-PAD.

PLX-PAD is a cellular therapeutic product derived from the placenta and is a ubiquitous source of adult stromal cells easily obtained without harm to the mother or baby.

For more information: www.pluristem.com


Related Content

News | Peripheral Artery Disease (PAD)

June 6, 2025 – A large retrospective review of more than 100,000 patients found the use of glucagon-like peptide-1 ...

Home June 06, 2025
Home
News | Peripheral Artery Disease (PAD)

Feb. 3, 2025 — Today, Peripheral Artery Disease (PAD) affects 10 million Americans and is the most common cause of limb ...

Home February 04, 2025
Home
News | Peripheral Artery Disease (PAD)

Jan. 13, 2025 – R3 Vascular Inc., a medical device company dedicated to treating peripheral arterial disease (PAD) ...

Home January 13, 2025
Home
News | Peripheral Artery Disease (PAD)

A new study reports persistent disparities in outcomes for people with peripheral artery disease (PAD) and its more ...

Home January 13, 2025
Home
News | Peripheral Artery Disease (PAD)

Dec. 13, 2024 – Sensome has announced positive results from two studies of its Clotild Smart Guidewire System ...

Home December 16, 2024
Home
News | Peripheral Artery Disease (PAD)

Nov. 18, 2024 — In November, Esperion presented an analysis from the CLEAR Outcomes study focused on patients with ...

Home December 03, 2024
Home
News | Peripheral Artery Disease (PAD)

Nov. 4, 2024 — Royal Philips recently announced enrollment of the first patient in the U.S. THOR IDE clinical trial ...

Home November 08, 2024
Home
News | Peripheral Artery Disease (PAD)

Sept. 16, 2024 – Shockwave Medical, Inc., part of Johnson & Johnson MedTech, has announced the full U.S. launch of the ...

Home September 16, 2024
Home
News | Peripheral Artery Disease (PAD)

Sept. 1, 2024 — September is Peripheral Artery Disease (PAD) Awareness Month, a time to educate and empower people to ...

Home September 04, 2024
Home
News | Peripheral Artery Disease (PAD)

May 16, 2024 — Timely diagnosis and proper management of peripheral artery disease (PAD), including coordinated care ...

Home May 16, 2024
Home
Subscribe Now